A long shot...Last Wednesday, I left a small grey hardshell suitcase on a train from London St Pancras to Cambridge between 5-6pm
The thing in it I'm most upset about losing is a five-year journal in which I've recorded moments with my daughter (now 7) that have made me laugh or smile, and how she's changed. I like to read them back to her so she knows how precious she is.
Nothing has turned up through the train companies' lost property systems yet, and I know that may take a while, but I don't want to leave a stone unturned. Any bright ideas? Know this is a long shot. @TLRailUK@GNRailUK
@RoyalMailHelp hello Royal Mail you have a parcel that is due to be delivered for me. I mistakenly put the wrong address. I need to amend the address so it can be delivered. Can you let me know how to do that please?
Allow me to jump in. #avct is a prime example of how the efficient market hypothesis should not be generalized. The 'investors' at AIM generally cannot compute the value of PRECISION; in fact, no one can accurately do so. What can safely be said is that PRECISION is a tremendously disruptive technology. The idea is not new, but it was deemed unfeasible. FAP was early on recognized as a therapy target of immense potential. But everyone who tried to give it a shot had failed.
You see, in the big picture of the history of chemo, it all started with Ehrlich's idea of a 'magical bullet' akin to an antibiotic specifically against cancer itself. That has stayed out of reach ever since. Then came the next best thing: highly toxic compounds derived from agents of chemical warfare, and thus chemo therapy was established. Far from the 'magical bullet,' chemo turned out to be a match of last man standing between patient and cancer, just who could tolerate more of those poisonous agents. The next logical step came in skewing the affinity of the poison towards cancer, that is, where we are now and what is dominating the global sales for chemotherapeutics. No one saw it coming that there would be an end to this line of development, so ADCs highly specific to certain phenotypes of cancers absorbed all research efforts almost fully. And now some peptide-startup from the UK took a step back and brought something dangerously similar to Ehrlich's 'magical bullet' forward. Do not think the players don't know what they got there. FAP-tracers are, as of now, revolutionizing diagnostics in nuclear medicine. But PRECISION is disruptive to BP as hell; it could destroy in a relatively short timespan all the big boys' blockbusters of today. So they know what is up here, but they are in no hurry to move up on it since it will force them to write off billions in research and disrupt the entire market. They stand by and watch—all of them. When one starts to move, they will descend like vultures. But it is in their mutual interest to let the current paradigm run its course undisturbed for as long as possible. That is, in a nutshell, why the investors on AIM cannot see the actual value, and the investors who can see it have a tremendous incentive not to act upon it so as not to accelerate this looming technological disruption until some competitor shows an intention to do so. Then it will be all hell, let loose.
We're delighted that Avacta has been shortlisted as a finalist for the 2024 @Citeline Scrip Awards in the 'Best Oncology R&D Advance' category. Find more info about the awards at https://t.co/0nphtYAy7Z #AVCT
#AVCT
Imagine a 60 year old male.
It could be you. Your husband. Your dad. The fun uncle you always loved seeing as a child.
In early 2021, he felt a lump behind his right knee. An ice pack didn’t help. Ibuprofen and physio exercises didn’t help. Finally he went to the doctor.
Biopsy.
Grade 3 undifferentiated pleomorphic sarcoma, a rare type of cancer.
Three months of radiotherapy followed by surgery. Viable tumour cells in under 10% of tumour volume - all seems well by September 2021.
By March 2022, he’s diagnosed with severe Stage 4 cancer which has spread to the membrane around his lungs.
By June 2022 options are running out, and he’s put on an early trial for a new combination therapy (Etigilimab + Nivolumab) for 6 months.
He has a 41% chance of grade 3+ treatment-emergent adverse effects which could be life threatening in themselves.
The disease continues to progress.
He then enrolls in the @avacta AVA6000 trial at the beginning of 2023.
Over the course of 11 months between February 2023 and January 2024, he has a near complete resolution of multiple metastatic lesions in the pleura (a -74% in the diameter of the lesions). See scans below.
During his time on AVA6000 (and last we heard he was still on drug 14 months later), his chances of developing neutropenia dropped by two-thirds compared to naked doxorubicin, and chances of febrile neutropenia dropped to 0%.
Importantly, quality of life has been greatly improved. AVA6000 boasts a 50% reduction in patients experiencing nausea, an over 50% reduction in patients experiencing decreased appetite, and the chances of experiencing pain or constipation decreasing 7 fold.
Bear in mind we are seeing this efficacy during a phase 1a safety and tolerability study.
Bear in mind this is only one patient - there are many others.
The data can only continue to get better.
In the near term, I suspect the precision platform will be linked to other drugs which are designed to have greater efficacy against other types of cancers for which doxorubicin is not the gold standard. This pipeline is due to be revealed by the end of the year.
Are Avacta worried cancers such as pancreatic, colorectal and biliary tract are only FAPmid not FAPhigh? No chance. The attached graph shows the platform works just as well in both circumstances.
This is real world stuff affecting real people just like me and you - already making a huge difference to treatment outcomes as well as quality of life during treatment.
Would you want yourself or your loved one on AVA6000 as opposed to standard doxorubicin? I would.
I eagerly await the data from the 2-weekly dosing schedule which are to be presented at @myESMO before we move into the phase 1b expansion cohorts later in the year.
Thoughts welcome, let’s continue to strive for progress.
@annals_Oncology@OncoAlert@ACSNews@EORTC@brunolarvol@MakisMD@CD_AACR@DrChoueiri@vivekSubbiah@Liz_ORiordan@JTrentMDPhD@Alegronchi@herbloong@MBCadvocate@Winette_vdGraaf@pawel_sobczuk@theNCI@CR_UK@VriesElisabeth
@TimGreten @jsoriamd@PTarantinoMD
@ElenaGarralda @NCIEytanRuppin @NEJM@Cancer_cell@NatureCancer@RonDePinho@Simocristea@DCalleMD@breelynwilkyMD@DrLaraDavis@sarcomapatients@t0mclark3@barneycalman@rebeccasmt@andrewgregory@eleanorhayward@richardhorton1@BBCHughPym@HSJEditor@ShaunLintern@Nicktriggle@dennis_campbell@Kamranabbasi
As leader of the Conservative Party, I will detach the United Kingdom from planet earth, attach -- British-built -- rockets to all four corners of our great country, and fly it into space. This is the only way to keep us safe from the threat posed to our values by reality.